Professional Documents
Culture Documents
Osimeritinib (Tagrisso) - Tagrisso 40Mg
Osimeritinib (Tagrisso) - Tagrisso 40Mg
OSIMERITINIB 40MG
DESCRIPTION
Tagrisso 40mg
INDICATION
A Tagrisso 40mg tablet is widely indicated as first line therapy for advanced non-small cell lung
cancer with EGFR mutation positive patients. Tagrisso 40mg is also used for the treatment of
patients affected with advanced EGFR T792M mutation positive NSCLC, disease has advanced
on or after the tyrosine kinase inhibitor treatment.
Tagrisso 40mg
MECHANISM OF ACTION
Osimeritinib is similar in action when compared to other tyrosine kinase inhibitor drugs.
Osimeritinib, Tagrisso 40mg tablet is named tyrosine kinase inhibitor of epidermal development
factor receptor which is available on the surface of tumor cells Osimeritinib is non-reversibly
converge with mutant type of EGFR at 9 folds than wild sort
Forbids EGFR sharpening changes exon 19 Del and L858R Prompts denies transformed EGFR
with T790M opposition transformation. At last, bring down action against wild kind EGFR
Tagrisso 40mg
ADME
Tagrisso 40mg
DOSAGE MANAGEMENT
The recommended dosage of the tablets are, 80mg tablet should be taken as a single
dose. Tagrisso 40mg tablet should be administered with or without food.If patient felt difficult to
swallow the Tagrisso 40mg tablets as such, must disperse the tablet in 60ml of noncarbonated
water and drink the solution immediately.
Tagrisso 40mg tablet do not break, crush or chew.
Interrupt the treatment during the conditions like;
Interstitial lung disease
QT prolongation
Symptomatic congestive heart failure
In pain management
Grade III or severe: discontinue the Tagrisso 40mg tablet for 3 weeks
Grade 0 to II: follow at 80mg or 40mg as a single dose
If no development in 3 weeks: Discontinue the therapy.
While co administration of Tagrisso 40mg with CYP3A4 inducers, the dosage of Tagrisso
40mg should be increased to 160mg as a single dose and followed by 80mg for 3 weeks after
discontinuation of strong CYP3A4 inducers.
Tagrisso 40mg
PRECAUTIONS
The most common adverse effects occurred during the therapy; Cardiomyopathy, QT
prolongation, Interstitial lung disease, Keratitis.
Other common side effect :
Diarrhea or constipation, Hyperglycemia, Hypomagnesemia, Hyponatremia, Elevation of AST &
ALT, Stomatitis, Nausea, Vomiting, Rash, Nail toxicity, Pruritus, Dry skin, Headache, Cough,
Dyspnea, Fatigue, Pyrexia, Loss of appetite, Respiratory tract infection, Lymphopenia,
Thrombocytopenia, Anemia, Neutropenia.
PREGNANCY
Pregnancy category of Osimeritinib is not designate While using Tagrisso 40mg tablet causes
possible for fetal harm
LACTATION
STORAGE
MISSED DOSE
In case of missed dose, do not take the missed dose and follow the regular dosing schedule.
CONTACT US
MAIL ID : millionhealthpharmaceuticals@gmail.com
PHONE NO : +91-9940472902
WEBSITE : https://millionpharma.com/osimeritinib-40mg.php